Oncotarget

Clinical Research Papers:

Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study

Huan Tong, Bo Wei, Shuang Chen, Yong-Mei Xie, Ming-Guang Zhang, Lin-Hao Zhang, Zhi-Yin Huang, Cheng-Wei Tang _

PDF |  HTML  |  Author Information  |  Order a Reprint

Oncotarget. 2017; 8:48303-48312. https://doi.org/10.18632/oncotarget.15684

Metrics: PDF 183 views  |   HTML 109 views  |   ?  


Abstract

Huan Tong1, Bo Wei1, Shuang Chen1, Yong-Mei Xie2, Ming-Guang Zhang1, Lin-Hao Zhang1, Zhi-Yin Huang1 and Cheng-Wei Tang1

1 Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China

2 Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China

Correspondence to:

Cheng-Wei Tang, email:

Keywords: hepatocellular carcinoma, transarterial chemoembolisation, celecoxib, lanreotide, survival

Received: October 07, 2016 Accepted: February 15, 2017 Published: February 24, 2017

Abstract

Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis. Cyclooxygenase-2 inhibitors and somatostatin analogues were reported to inhibit tumour angiogenesis. The pilot randomized controlled trial was aimed to prospectively evaluate the protocol of TACE combined with celecoxib and lanreotide (TACE+C+L) in patients with unresectable and advanced HCC. A total of 71 patients with HCC were enrolled and randomly assigned to either TACE (n=35) or TACE+C+L (n=36) group. Overall survival, disease control rate (DCR), and adverse events were assessed during a 3-year follow-up period. The median overall survival of the TACE+C+L group (15.0 months) was doubled compared to that of TACE group (7.5 months), p = 0.012. DCR of the TACE+C+L group was significantly higher than that of the TACE group either at 6 months (72.2% vs 42.9%, p = 0.012) or at 12 months (61.1% vs 28.6%, p = 0.006). The median overall survivals (13 months vs 4.5 months, p = 0.013) and DCR at 12 months (50% vs 13.6%, p = 0.008) of patients with advanced HCC in TACE+C+L groups were significantly higher than those in TACE group. No significant difference of adverse events was observed between the two groups. The occurrence of post-embolisation syndrome in TACE+C+L group was significantly lower than that in TACE group (16.7% vs 60.0%, p = 0.001). In conclusion, the regimen of TACE+C+L prolonged overall survival, enhanced tumour response, reduced post-embolisation syndrome and was well-tolerable in the patients with unresectable HCC. It may be more beneficial for advanced HCC.

Author Information

Huan Tong

Bo Wei

Shuang Chen

Yong-Mei Xie

Ming-Guang Zhang

Lin-Hao Zhang

Zhi-Yin Huang

Cheng-Wei Tang
Primary Contact  _


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15684